DENTSPLY SIRONA (NASDAQ:XRAY) Downgraded by Zacks Research to Strong Sell

Zacks Research downgraded shares of DENTSPLY SIRONA (NASDAQ:XRAY) from a hold rating to a strong sell rating in a research note released on Monday,Zacks reports.

A number of other research firms have also recently commented on XRAY. Weiss Ratings restated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Friday, October 30th. JPMorgan Chase & Co. dropped their price target on shares of DENTSPLY SIRONA from $12.00 to $10.00 and set a “neutral” rating on the stock in a research note on Friday, November 6th. Barclays boosted their price target on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a report on Monday, August 24th. Leerink Partners reduced their price objective on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating for the company in a research report on Wednesday, October 14th. Finally, BMO Capital Markets decreased their price objective on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating on the stock in a report on Thursday, September 17th. Three research analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $12.42.

DENTSPLY SIRONA Trading Up 1.7%

XRAY stock opened at $9.70 on Monday. The company’s 50-day simple moving average is $9.54 and its 200-day simple moving average is $11.25. The company has a quick ratio of 1.04, a current ratio of 1.63 and a debt-to-equity ratio of 1.47. DENTSPLY SIRONA has a 52-week low of $8.14 and a 52-week high of $14.76. The firm has a market cap of $1.92 billion, a P/E ratio of -15.64, a PEG ratio of 1.36 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.02). The business had revenue of $836.00 million during the quarter, compared to analysts’ expectations of $861.68 million. DENTSPLY SIRONA had a negative net margin of 3.38% and a positive return on equity of 20.21%. DENTSPLY SIRONA’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.37 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. As a group, equities analysts forecast that DENTSPLY SIRONA will post 1.24 EPS for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently made changes to their positions in XRAY. BlackRock Inc. purchased a new stake in shares of DENTSPLY SIRONA during the second quarter worth approximately $283,405,000. Southpoint Capital Advisors LP acquired a new position in DENTSPLY SIRONA in the 1st quarter valued at $116,000,000. Edmond DE Rothschild Holding S.A. lifted its holdings in DENTSPLY SIRONA by 1.4% in the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 4,568,300 shares of the medical instruments supplier’s stock valued at $40,475,000 after purchasing an additional 65,000 shares in the last quarter. Paradigm Capital Management Inc. NY purchased a new position in DENTSPLY SIRONA in the 2nd quarter valued at $39,775,000. Finally, Dimensional Fund Advisors LP boosted its stake in DENTSPLY SIRONA by 31.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,559,388 shares of the medical instruments supplier’s stock worth $41,284,000 after purchasing an additional 850,261 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc. develops, manufactures and markets products and technologies for dental professionals. Its portfolio includes dental equipment and imaging systems, digital dentistry and CAD/CAM solutions, dental implants, endodontic and restorative products, and supplies used in preventive care. The company serves dental practices, laboratories and other customers around the world. Its products support a range of clinical activities, including diagnosis, treatment planning, restorative dentistry and oral hygiene.